NAPLES, Fla., Feb. 9, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
Read More
Advancing pipeline with naturally occurring and synthetic compounds initially focused on the development of cannabinoids for pharmaceutical use Enveric has assembled a highly accomplished executive team, Board of Directors and…
Read More
NAPLES, Fla., Jan. 15, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing…
Read More
NAPLES, Fla., Jan. 12, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it…
Read More
Industry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape NAPLES, Fla., Jan. 5, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to…
Read More
